Collectively, these data support the hypothesis that the combination of MEK and CDK4/6 inhibitors induces tumor regression via the cooperative induction of cell cycle arrest, and that Ki67 and pS6 may serve as surrogates for combined target engagement. The gene discussed is CDK4; the disease is neoplasm.